ϸ°ûÉúÎïѧÂÛÎÄ

Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ÉúÎïѧÂÛÎÄ > ϸ°ûÉúÎïѧÂÛÎÄ >

Ѫ¹ÜÄÚƤ×æϸ°ûÓë»ùÒòÖÎÁÆ̽Îö

À´Ô´£ºÖйúÉúÎïÖÆƷѧÔÓÖ¾ ×÷ÕߣºÀîÐÀ;½¯ÈçÈç;¹þСÇÙ
·¢²¼ÓÚ£º2020-05-07 ¹²10606×Ö

¡¡¡¡Õª    Òª£º¡¡Ëæ×ÅѪ¹ÜÄÚƤ×æϸ°û(endothelial progenitor cell,EPC)Ñо¿µÄÉîÈ룬EPCµÄ·ÖÀë¡¢ÌåÍâÅàÑø¡¢¼ø¶¨¼°ÔÚѪ¹ÜÏà¹ØÐÔ¼²²¡(ÈçȱѪÐÔ¼²²¡)ºÍ¸÷ÖÖÖ×Áö·¢Éú·¢Õ¹ÖеÄ×÷Óü°¹¦ÄÜÒѳÉΪеÄÑо¿Èȵ㡣EPC¾ßÓзֻ¯¹¦ÄÜ£¬ÔöÖ³ÄÜÁ¦¼«Ç¿£¬ÌåÍâÀ©ÔöÅàÑøËٶȿ죬Ö÷Òª´æÔÚÓÚÍâÖÜѪ¡¢ÆêѪ¡¢¹ÇËèÖУ¬ÇÒÈÝÒ×»ñÈ¡£¬ÊǸÉϸ°ûÒÆÖ²ÁÆ·¨ÀíÏëµÄÖÖ×Óϸ°ûÀ´Ô´¡£Ä¿Ç°£¬EPCÔÚÖÎÁÆÐÄÄÔѪ¹Ü¡¢Ö«ÌåȱѪÐÔ¼²²¡µÈ·½ÃæµÄÑо¿Ê®·Ö»îÔ¾£¬²¢³õ²½È¡µÃÁ˿϶¨µÄ³É¹û¡£±¾ÎÄÖ÷Òª¾ÍEPCÔÚÔÙÉúҽѧÖеÄϸ°ûÖÎÁƼ°»ùÒòÖÎÁÆÉϵÄÓ¦ÓÃ×÷Ò»×ÛÊö¡£

¡¡¡¡¹Ø¼ü´Ê£º¡¡ÄÚƤ×æϸ°û; ÔÙÉúҽѧ; ϸ°ûÖÎÁÆ; »ùÒòÖÎÁÆ;

¡¡¡¡Abstract£º¡¡With the further study of endothelial progenitor cell(EPC),the isolation,in vitro culture and identification of EPC and their roles in the pathogenesis and progress of vascular diseases such as ischemic diseases as well as various tumors have become the new focus in the field of research. EPC have a differential function and strong proliferation ability and were propagated rapidly in vitro,which mainly exist in peripheral blood,umbilical cord blood and born marrow and is an ideal source of cell seed for stem cell transplantation therapy. At present,EPC were researched actively in the field of therapy of cardiovascular and cerebrovascular diseases and limb ischemic diseases,in which the definite achievements have been obtained. This paper describes the application of EPC in cell therapy and gene therapy in regenerative medicine.

¡¡¡¡Keyword£º¡¡Endothelial progenitor cell(EPC); Regenerative medicine; Cell therapy; Gene therapy;

¡¡¡¡ÔÙÉúҽѧÊÇÒ»¸öÉæ¼°¸Éϸ°û¡¢×éÖ¯¹¤³Ì¡¢Ï¸°ûÓë·Ö×ÓÉúÎïѧ¡¢·¢ÓýÉúÎïѧ¡¢ÉúÎﻯѧµÈ¶à¸öѧ¿ÆÁìÓòµÄÐÂÐËѧ¿Æ£¬ÊÇͨ¹ýÑо¿»úÌåµÄÕý³£×éÖ¯ÌØÕ÷¼°¹¦ÄÜ¡¢´´ÉËÐÞ¸´¼°ÔÙÉú»úÖƺ͸Éϸ°û·Ö»¯»úÖÆ£¬Ñ°ÕÒÓÐЧµÄÉúÎïÖÎÁÆ·½·¨£¬´Ù½ø»úÌå×ÔÎÒÐÞ¸´¼°ÔÙÉú£¬»ò¹¹½¨ÐµÄ×éÖ¯¼°Æ÷¹Ù£¬ÒÔ¸ÄÉÆ»ò»Ö¸´ËðÉË×éÖ¯ºÍÆ÷¹Ù¹¦ÄܵÄѧ¿Æ£¬Ö÷Òª°üÀ¨¸Éϸ°û¡¢×éÖ¯¹¤³Ì¡¢Ï¸°ûÖÎÁÆ¡¢Æ÷¹ÙÒÆÖ²µÈ¶à¸öÑо¿ÁìÓò¡£½üÄêÀ´Ëæ×Åϸ°ûÉúÎïѧÓÈÆäÊǸÉϸ°ûÉúÎïѧµÄ·ÉËÙ·¢Õ¹£¬Ï¸°ûÖÎÁÆÔÚ»ù´¡Ñо¿ÁìÓòÈ¡µÃÁ˺ܴóµÄ½øÕ¹£¬²¿·Ö»ù´¡Ñо¿³É¹ûÒÑ¿ªÊ¼ÔÚÐÄѪ¹Üϵͳ¼²²¡¡¢Éñ¾­ÏµÍ³¼²²¡¡¢¼¡Èâ¹Ç÷ÀÏà¹Ø¼²²¡¡¢ÌÇÄò²¡µÈ¶àÖÖ¼²²¡µÄÁÙ´²ÊÔÑéÖеõ½Ó¦Ó㬲¢È¡µÃÁ˳õ²½µÄÑо¿³É¹û£¬Õ¹Ê¾Á˹ãÀ«µÄÁÙ´²Ó¦ÓÃÇ°¾°¡£Ñª¹ÜÄÚƤ×æϸ°û£¨endothelial progenitor cell,EPC£©×÷ΪÖÎÁÆȱѪÐÔ¼²²¡µÄºòѡϸ°û£¬¾ßÓÐÒ×ÓÚ´ÓÍâÖÜѪÖлñµÃ¡¢ÓÐЧµÄѪ¹ÜÉú³ÉºÍѪ¹ÜÉú³ÉЧӦ¡¢ÑªÍ³µÄÎȶ¨ÐԺͽϵ͵ÄÖÂÁöÐÔµÈÌØÕ÷£¬ÕâЩÌØÕ÷ÒýÆðÁËÐí¶à¹ØÓÚÆäÖÎÁÆÐÔÐÂѪ¹ÜÐγɵĿÉÄÜЧÓõÄÑо¿¡£ÔìѪEPCÓÉÓÚÆäÀûÓÚÌáÈ¡ºÍ·ÖÀ룬ÀûÓÚÌåÍâÅàÑøºÍÀ©Ôö£¬ÔÚÕâЩӦÓÃÖоßÓÐÒ»¶¨µÄDZÁ¦¡£
 

Ѫ¹ÜÄÚƤ×æϸ°ûÓë»ùÒòÖÎÁÆ̽Îö
 

¡¡¡¡1 ¡¢Ï¸°ûÖÎÁÆ

¡¡¡¡1.1¡¢ EPCÒÆÖ²ÖÎÁÆȱѪÐÔÐÄÔಡ

¡¡¡¡1.1.1 ¡¢¾­¹Ú×´¶¯ÂöÒÆÖ²

¡¡¡¡2010Ä꣬SENµÈ[1]ͨ¹ýÌåÍâÀ©ÕÅ£¬¶Ô¹ÇËèÔ´ÐÔEPCµÄÔÙÉúDZÁ¦½øÐÐÁ˵÷Õû£¬ÒÔÖÎÁÆÐļ¡È±Ñª¡£ËûÃÇͨ¹ýÓÐЧµÄ»ùÒò¸ÄÔìÀ´Ìá¸ßEPCµÄ¹¦ÄÜ£¬ÔÚ´óÊóÐļ¡¹£ËÀÄ£ÐÍÖУ¬ÀûÓÃÏÙÏà¹Ø²¡¶¾£¨adeno-associated virus,AAV£©À©´óºÍתµ¼ÖÜΧµÄѪҺEPC¡£Í¨¹ý×óÇ°½µ¹Ú×´¶¯Âö×èÈû¶øÐļ¡¹£ËÀµÄ³ÉÄê´óÊ󣬽ÓÊܾ­¹Ú×´¶¯ÂöÒÆÖ²µÄAAV-IGF-1תµ¼µÄ×ÔÌåEPC£¬½á¹ûÏÔʾ£¬±í´ïIGF-1µÄEPCµ¼ÖÂÐļ¡Ï¸°ûµòÍö¼õÉÙ£¬Ðļ¡Ï¸°ûÔöÖ³Ôö¼Ó£¬¹£Èû²¿Î»Ã«Ï¸Ñª¹ÜÊýÁ¿Ôö¼Ó¡£Òò´Ë£¬¾­¹Ú×´¶¯ÂöÒÆÖ²µÄ±í´ïIGF-1µÄEPCÔÚ´óÊóÐÄÔ๣ÈûÖбíÏÖ³öÁ¼ºÃµÄϸ°û±£»¤×÷Óá£2015Ä꣬LEEµÈ[2]Ìá³öÒ»¸ö¼ÙÉ裬¼´¶ÔÓÚ²»ÊʺϽøÐйÚ×´¶¯Âö½éÈëÖÎÁƵÄÑÏÖØÃÖÂþÐÔ¹Ú×´¶¯Âö¼²²¡»¼ÕßµÄȱѪÏà¹ØÐÔ×óÐÄÊÒ¹¦ÄÜÕÏ°­£¬¿Éͨ¹ýÀ´Ô´ÓÚÍâÖÜѪµÄÑ­»·Ê½×ÔÌåCD34+ϸ°ûÄÚ¹Ú×´¶¯ÂöÊäѪµÃµ½¸ÄÉÆ¡£ËûÃǽøÐÐÁËһϵÁеÄÁÙ´²ÊÔÑ飬ÒÔ²âÊÔÁ½ÖÖ²»Í¬Å¨¶ÈµÄCD34+ϸ°ûÔÚÑÏÖØÃÖÂþÐÔ¹Ú×´¶¯Âö¼²²¡ÖÐÖÎÁƵÄÓÐЧÐԺͰ²È«ÐÔ£¬²¢Í¬Ê±ÑéÖ¤ÁËÀ´Ô´ÓÚÍâÖÜѪµÄÑ­»·Ê½×ÔÌåCD34+ϸ°ûÄÚ¹Ú×´¶¯ÂöÊäѪµÄϸ°ûÁÆ·¨¶ÔÓÚ²»ÊʺϹÚ×´¶¯Âö½éÈëÖÎÁÆÇÒÒ©ÎïÁÆ·¨·´Ó¦²îµÄÑÏÖØÃÖÂþÐÔ¹Ú×´¶¯Âö¼²²¡»¼ÕßµÄÐŦÄÜÊÇ·ñÊÇ°²È«ÓÐЧµÄ¡£ÔÚÑо¿ÖУ¬ÄÉÈëÁË38Àý»¼ÓÐÑÏÖØÃÖÉ¢ÐÔ¹Ú×´¶¯Âö¼²²¡µÄ»¼Õߣ¬²¢Ëæ»ú·ÖΪ2×飬·Ö±ð¾­¹Ú×´¶¯Âö×¢ÉäŨ¶ÈΪ1.0×107ºÍ3.0×107¸öµÄCD34+ϸ°û£¬Í¨¹ýËæ·ÃºÍµ÷²éºó£¬½á¹ûÏÔʾ£¬¾­¹Ú×´¶¯ÂöÒÆÖ²CD34+ϸ°ûºó£¬Á½×黼Õß¹Ú×´ñ¼ÑªÒºÑù±¾ÖеÄEPCº¬Á¿¸ßÓÚÍâÖÜѪҺ£¬×óÐÄÊÒÉäѪ·ÖÊýÔö¼Ó£¬ÐĽÊÍ´ºÍÐÄÁ¦Ë¥½ßµÃµ½¸ÄÉÆ¡£Òò´Ë£¬¾­¹Ú×´¶¯ÂöÒÆÖ²µÄCD34+ϸ°ûÁÆ·¨¶ÔÓÚ²»ÊʺϹÚ×´¶¯Âö½éÈëÖÎÁÆÇÒÒ©ÎïÁÆ·¨·´Ó¦²îµÄÑÏÖØÃÖÂþÐÔ¹Ú×´¶¯Âö¼²²¡»¼ÕßµÄÐŦÄÜÊÇ°²È«ÓÐЧµÄ¡£

¡¡¡¡1.1.2 ¡¢¾­ÐÄÍâĤÐļ¡×¢ÉäÒÆÖ²

¡¡¡¡2014Ä꣬KAMATAµÈ[3]ͨ¹ýʵÑé֤ʵÁË°éËæEPCÐÄÍâĤÐļ¡×¢ÉäÓÕµ¼ÒÆÖ²µÄÐÄÔà¸Éϸ°ûÔÚÖÎÁÆÂýÐÔȱѪÐÔÐļ¡²¡ÖУ¬±ÈÓÃÐÄÔà¸Éϸ°ûµ¥¶ÀÖÎÁÆ£¬Äܹ»½øÒ»²½´Ù½øÐÂÉúѪ¹ÜµÄÐγɺÍÐļ¡ÏËά»¯µÄ¼õÉÙ£¬ËµÃ÷°éËæEPCÐÄÍâĤÐļ¡×¢ÉäµÄÐÄÔà¸Éϸ°û¶ÔÂýÐÔȱѪÐÔÐļ¡²¡µÄÖÎÁÆЧ¹û½Ïµ¥¶ÀÒÆÖ²ÐÄÔà¸Éϸ°û¸ü°²È«ÓÐЧ¡£QUANµÈ[4]ͨ¹ýһϵÁÐÊÔÑéÑо¿ÁËÐØÏÙËØβ4(Tβ4£©¶ÔTβ4´¦ÀíµÄEPCÔÚ¹£ÈûÐļ¡Öо­Ðļ¡ÄÚ×¢Éäºó¶ÔѪ¹ÜÉú³ÉºÍÐÄÔ๦ÄܵÄÓ°Ïì¡£ËûÃÇ´Ó³ÉÄêÐÛÐÔ´óÊóµÄ¹ÇËèÖзÖÀëEPC£¬²¢ÔÚÄÚƤ»ù´¡ÅàÑø»ù-2ÖзõÓý£¬È»ºó·Ö±ðÓÃŨ¶È0.05¡¢0.1ºÍ0.2μmol/LµÄTβ4´¦Àíϸ°û£¬Í¬Ê±ÓÃDMEM·õÓýµÄϸ°û×÷Ϊ¶ÔÕÕ£¬½á¹û±íÃ÷£¬Tβ4Äܹ»ÔöÇ¿EPCµÄ»îÁ¦£¬´Ù½øϸ°ûÔöÖ³ºÍǨÒÆÒÔ¼°Ï¸°ûÄÚëϸѪ¹ÜÑù½á¹¹µÄÐγɣ¬»¹ÄÜÔö¼Óϸ°ûÖÐp-AktµÄ±í´ï£¬¾­Tβ4´¦ÀíµÄEPC¿É¸ÄÉÆÐļ¡¹¦ÄÜ£¬ÔöÇ¿¹£ÈûÐļ¡µÄÐÞ¸´£¬´Ù½ø¹£ËÀÐļ¡ÒÆÖ²ºóµÄѪ¹ÜÐÂÉú£¬Òò´Ë£¬ÓÃTβ4Ô¤´¦ÀíEPC¿ÉÄÜÊÇÐļ¡¹£ËÀÒÆÖ²ºóȱѪ×éÖ¯ÐÞ¸´µÄвßÂÔ¡£µ«¾­ÐÄÍâĤÐļ¡ÄÚ×¢ÉäEPCÒÆÖ²ÓÕ·¢ÊÒÐÔÐÄÂÉʧ³£µÄ·çÏÕÉÐÐè½øÒ»²½¹Û²ì¡£

¡¡¡¡1.1.3 ¡¢¾­ÐÄÄÚĤÐļ¡×¢ÉäÒÆÖ²

¡¡¡¡2015Ä꣬PREMERµÈ[5]Ìá³öÁ˼äÖʸÉϸ°û£¨mesenchymal stem cells,MSC£©Äܹ»Ôö¼ÓEPCµÄ¹¦Äܺͻָ´ÑªÁ÷½éµ¼µÄѪ¹ÜÊæÕŵļÙÉè¡£ÔÚÑо¿ÖУ¬ÌØ·¢ÐÔÀ©ÕźÍȱѪÐÔÐļ¡²¡»¼Õß±»Ëæ»ú·ÖÅä½ÓÊÜ×ÔÌå»òͬÖÖÒìÌåµÄMSC£¬±È½ÏÁËMSC¾­ÐÄÄÚĤעÉäÇ°ºó3¸öÔÂÒÔ¼°½¡¿µ¶ÔÕÕ×éµÄEPC-¼¯ÂäÐγɵ¥Î»¼°Ñª¹ÜÊæÕŹ¦ÄܺÍѪ¹ÜÄÚƤÉú³¤Òò×ÓµÄÑ­»·Ë®Æ½£¬½á¹ûÏÔʾ£¬MSCÄܹ»µ¼Ö¹¦ÄÜÐÔEPCµÄÔöÖ³ºÍѪ¹Ü·´Ó¦ÐԵĸÄÉÆ£¬´Ó¶øʹÐÄÁ¦Ë¥½ß»¼ÕßµÄÄÚƤ¹¦Äָܻ´Õý³£¡£

¡¡¡¡1.1.4 ¡¢ÍâÖÜѪ¹ÜÄÚ×¢ÉäÒÆÖ²

¡¡¡¡EPC¾­ÍâÖÜѪ¹ÜÄÚ×¢ÉäÒÆÖ²µÄÓŵã°üÀ¨ÒÆÖ²¼òµ¥¡¢Ò×ÐС¢²»ÐèÒª¸´ÔÓÉ豸ºÍ¼¼ÊõÒÔ¼°¿Éͨ¹ýѪҺѭ»·¶¨ÆÚ¡¢¶¨Ê±¡¢³ÖÐøÏòȱѪ²¡±ä²¿Î»½øÐÐÒÆÖ²£¬´Ó¶øά³ÖȱѪ×éÖ¯ÓÐЧµÄEPCŨ¶ÈÌá¸ßÁÆЧ¡£Ñо¿±íÃ÷£¬¼¯Âäϸ°û´Ì¼¤Òò×Ó[6]¡¢Ñª¹ÜÄÚƤÉú³¤Òò×Ó[7]µÈϸ°ûÒò×ÓÒÔ¼°Ñª¹Ü½ôÕÅËØת»»Ã¸ÒÖÖƼÁ[8]¡¢´Ùºìϸ°ûÉú³ÉËØ[9]¡¢ËûÍ¡Ààµ÷Ö¬Ò©[10]¡¢ÒøÐÓÒ¶ÌáÈ¡Îï[11]µÈ¾ù¾ßÓж¯Ô±EPCµÄ¹¦ÄÜ£¬ÈçHONOLDµÈ[12]¶ÔÂýÐÔÐÄË¥»¼Õß×¢É伯Âäϸ°û´Ì¼¤Òò×Óºó·¢ÏÖ£¬¼¯Âäϸ°û´Ì¼¤Òò×Ó²»½ö¿ÉʹÔìѪ¸Éϸ°û¼°EPCÔÚÍâÖÜѪÖеÄÊýÁ¿Ôö¼Ó£¬»¹ÓдٽøEPCµÄÐļ¡ÔÙÉú¼°ÐÂÉúѪ¹ÜÐγɵŦÄÜ¡£

¡¡¡¡1.2¡¢ EPCÔ¤·ÀÖ§¼ÜÊõºóÔÙÏÁÕ­

¡¡¡¡ÔÚÔÙÉúҽѧÖÐÒÔEPCΪÖÐÐĵÄÁíÒ»¸öÖ÷ÒªÑо¿¿ÎÌâÊÇΧÈÆÐÄѪ¹ÜÓ¦ÓõIJ¶»ñÖ§¼Ü£¬Æ佫EPC´ÓѪҺѭ»·ÖиôÀë³öÀ´£¬ÒÔ´Ù½øÂ㶵ÄÇ»±íÃæµÄÄÚƤ»¯¡£²¶»ñÊÇÓɹ̶¨»¯¿¹ÌåÔÚÖ§¼Ü±íÃæ²úÉúµÄ£¬Í¨³£ÊÇÕë¶ÔCD34¡£½üÄêÀ´µÄÑо¿±íÃ÷[13]£¬¿¹Ìå½áºÏÒѾ­±»Ö¤Ã÷¿ÉÒÔ¶Û»¯±íÃ棬¼õÉÙѪС°å𤸽ºÍÄýѪЧӦÒÔ¸ÄÉÆѪҺÏàÈÝÐÔ¼ì²â¡£

¡¡¡¡ÔÚEPC²¶»ñÖ§¼ÜÉϽøÐеÄËæ»úÁÙ´²ÊÔÑé±íÃ÷ÆäÊÇ°²È«ÓÐЧµÄ£¬Í¬Ê±Í¨¹ýÉÏÊкóµÄ¼à²â£¬²¢ÎÞÖ¤¾Ý±íÃ÷ʹÓúó²»Á¼ÐÄÔàʼþµÄ·çÏÕÔö¼Ó[14]¡£ÓëÒ©ÎïÏ´ÍÑÖ§¼Ü£¨drug-eluting stents,DES£©Ïà±È£¬EPC²¶»ñÖ§¼ÜÓëÍíÆÚ¹ÜÇ»¶ªÊ§ºÍ°ÐѪ¹ÜË¥½ßÓйأ¬µ«ÍíÆÚÖ§¼ÜÄÚѪ˨Ðγɵķ¢ÉúÂʽµµÍ¡£OrbusNeichÉú²úÁËÐÂÒ»´úEPC²¶»ñÖ§¼Ü“COMBO”£¬Æ佫Î÷ÂÞĪ˾ϴÍÑ180 d£¬´Ó¶ø½«DESµÄ¹¦Ð§Óë“ÉúÎ﹤³ÌÖ§¼Ü”µÄ³¤ÆÚ°²È«ÐÔ½áºÏÆðÀ´[15]¡£Ä¿Ç°£¬ÎªÁËÂú×ã¿ìËÙÄÚƤ»¯µÄÐèÒª£¬ÓÐÑо¿ÕßÈÏΪӦ¸ÃרÃÅÕë¶ÔÍíÆÚEPCÉõÖÁÊÇÑ­»·EC£¬¶øÍ¿Óп¹CD309»òCD144¿¹ÌåµÄ±íÃæÓë¸ÄÉƵÄÄÚƤ»¯½á¹ûÓйء£2015Ä꣬CHENµÈ[16]½øÒ»²½ÐÞ¸ÄÁ˲¶»ñ±íÃ棬ÒÔ´Ù½ø²¶»ñϸ°ûµÄתȾ£¬Í¨¹ýÌá³öÒ»ÖÖÊÊÌå-siRNAǶºÏÌåÐÞÊεÄ×éÖ¯¹¤³ÌѪ¹Ü£¬Ê¹Æä¿ÉÒÔÔÚÌÇÄò²¡Öб£³Öͨ³©ÐÔ£¬ÕâÖÖ×éÖ¯¹¤³ÌѪ¹ÜÓÉCD133-ÏÙÜÕ¼¤Ã¸£¨adenosine kinase,A.DK£©Ç¶ºÏÌåºÍÖ§¼Ü×é³É£¬×îÖÕµÄʵÑé½á¹ûÏÔʾ£¬CD133-ADKǶºÏÌå¿ÉÒÔÔÚÌåÄÚÑ¡ÔñÐÔ²¶»ñCD133ÑôÐÔϸ°û£¬²¶»ñµÄϸ°û¿ÉÒÔÄÚ»¯½áºÏµÄǶºÏÌåÒÔʵÏÖRNA×ÔÉíתȾ£¬×ªÈ¾ºóµÄSi RNA¿ÉÒÖÖÆCD133ÑôÐÔϸ°ûµòÍö£¬´Ó¶øµ¼ÖÂÁËÏÙÜÕµÄÉϵ÷£¬¸ÄÉÆÁËEPCµÄ¹¦ÄÜ¡£WOUDSTRAµÈ[17]ͨ¹ýÑо¿ÆÀ¼ÛÁË×éºÏÖ§¼ÜʹÓÃ1ÄêµÄ°²È«ÐÔºÍÁÙ´²½á¹û£¬±¨¸æÄÉÈëÁË2013Äê6Ô¡«2014Äê3Ô¼䣬¹²1 000Àý»¼Õߣ¬Ó¦ÓÃͬʱЯ´øÀ×ÅÁùËØÉúÎï¿É½µ½âÍ¿²ãºÍCD34+¿¹ÌåÍ¿²ãµÄÐÂÐÍÉúÎï×éºÏÖ§¼Ü£¬Ä¼¼¯EPCÒÔ´Ù½øѪ¹ÜÖØËÜ£¬´Ó¶ø·ÀÖ¹ÄÚĤÔöÉúºÍÔÙÏÁÕ­¡£½á¹ûÏÔʾ£¬³öÏÖ¼±ÐÔ¹Ú×´¶¯Âö×ÛºÏÕ÷µÄ»¼ÕßÕ¼49.9%£¬·¢Éú°Ð²¡±äʧ°ÜÂÊ£¨target lesion failure,TLF£©µÄ»¼ÕßÕ¼5.7%£¬·¢ÉúÐÄÔ´ÐÔËÀÍöµÄ»¼ÕßÕ¼1.7%£¬°ÐѪ¹ÜÐļ¡¹£ËÀ£¨myocardial infarction,MI£©ºÍ°Ð²¡±äѪÔËÖؽ¨£¨target lesion revascularization,TLR£©·¢ÉúÂÊ·Ö±ðΪ0.7%ºÍ4.4%£¬Ö§¼ÜÄÚѪ˨ÐγɵĻ¼ÕßÕ¼0.5%¡£¸ÃÑо¿±íÃ÷£¬ÔÚ»¼ÕßÖÐÓ¦ÓÃÐÂÐÍ×éºÏÉúÎïÖ§¼Ü1ÄêµÄÁÙ´²½á¹ûÀíÏë¡£ÓÃÓÚ²¶»ñºÍ²ûÃ÷EPCµÄ·Ö»¯ºÍ¹¦ÄÜÖеÄÖ÷ÒªÐźŴ«µ¼ÍøÂçµÄ¸üÇåÎúµÄ±íÃ濹ԭ¶¨Ò壬¿ÉÄÜΪEPC²¶»ñÖ§¼ÜÌṩ¸üºÏÀíµÄÉè¼Æ¡£È»¶ø£¬¹ÜÇ»±íÃæµÄÔÙÉúÈÔÈ»ÊÇѪ¹Ü×éÖ¯¹¤³ÌÖеĹؼüÎÊÌ⣬´ó¶àÊýŬÁ¦¼¯ÖÐÓÚÔÚÖ²ÈëÇ°ÓÃÄÚƤϸ°û“Ô¤ÖÔǻ±íÃæ¡£µ«Ñо¿±íÃ÷£¬ÕâÖÖÌåÍâÄÚƤ»¯·½·¨Ðè´óÁ¿Ê±¼äºÍ½Ï¸ß³É±¾£¬Òò´ËÊDz»ÇÐʵ¼ÊµÄ¡£¼øÓÚ´Ë£¬Ä¿Ç°Ðí¶àÑо¿»î¶¯¾ù¼¯ÖÐÔÚ²ÉÓᢿª·¢ºÍ¸Ä½øѪ¹ÜÒÆÖ²µÄEPC²¶»ñ¼¼ÊõÉÏ¡£

¡¡¡¡1.3 ¡¢EPCÖÎÁÆȱѪÐÔÄÔѪ¹Ü²¡

¡¡¡¡MEAMARµÈ[18]ͨ¹ýÊÔÑéÆÀ¹ÀÁËÑ­»·EPCÔÚ¶ÌÔÝÐÔÄÔȱѪ·¢×÷£¨transient ischemic attack,TIA£©»¼ÕßÖжÔδÀ´ÄÔѪ¹Ü£¨cerebral vessels,CV£©Ê¼þµÄ×÷Óã¬ÔÚÊÔÑéÖУ¬ÄÉÈëÁË30ÃûÁ¬ÐøµÄTIA»¼ÕߺÍ30Ãû½¡¿µÖ¾Ô¸Õß¡£30Ãû»¼ÕßÁ¬ÐøTIA 24 hºó£¬Ê¹ÓÃÁ÷ʽϸ°ûÊõ²â¶¨Ñ­»·EPCˮƽ£¬Í¬Ê±Ò²¶Ô30Ãû½¡¿µÖ¾Ô¸ÕßEPCˮƽ½øÐÐÁËÆÀ¹À£¬ÔÚ12¸öÔµÄʱ¼äÄÚ£¬ËùÓл¼ÕßÓɾ­Ñé·á¸»µÄÉñ¾­¿ÆҽʦÆÀ¹ÀÓÉCV¼²²¡ÒýÆðµÄ¸´·¢ÐÔTIA¡¢Öзç»òËÀÍö¡£½á¹ûÏÔʾ£¬Óë¶ÔÕÕ×éÏà±È£¬TIAÊ״η¢×÷ºó»¼Õß×éÑ­»·EPCÔö¼Ó£¬ÇÒÔÚµÚ1´ÎTIA·¢×÷ÖУ¬EPCÉý¸ßµÄ»¼Õßδ·¢ÉúδÀ´CVʼþµÄ·¢ÉúÂÊÔö¼Ó¡£LIµÈ[19]֤ʵÁËתȾ֬ÁªËØ»ùÒòµÄEPCÁªºÏÒÆÖ²ÎïÒÆÖ²ÖÁÄÔȱѪ´óÊóÄ£ÐÍÖУ¬¿É¸ÄÉÆ´óÊó´óÄÔÖж¯Âö±ÕÈûºóµÄ¹¦Äָܻ´£¬Í¬Ê±Ò²ËµÃ÷ÁË»ùÒòÐÞÊεÄϸ°ûÁÆ·¨¿ÉÄܶÔÖÎÁÆȱѪÐÔÖзçÓÐЧ¡£MORANCHOµÈ[20]±¨µÀ£¬×éÖ¯»ùÖʽðÊôµ°°×ø9Äܹ»Ó°ÏìȱѪºóEPCÓÕµ¼µÄѪ¹ÜÉú³É£¬ÆäÔÚÖзçºóEPCÓÕµ¼µÄѪ¹ÜÖØËÜÖÐÆð¹Ø¼ü×÷Óá£GENGµÈ[21]ͨ¹ýʵÑé̽ÌÖÁËÔÚÌÇÄò²¡Ð¡ÊóÄÔȱѪºó£¬EPCÒÆÖ²¶ÔѪÄÔÆÁÕÏÍêÕûÐÔµÄÓ°Ïì¡£ÔÚʵÑéÖУ¬ÌÇÄò²¡Ð¡Êó¾­Àú90 min¶ÌÔÝÐÔ´óÄÔÖж¯Âö±ÕÈûÊÖÊõ£¬²¢ÔÚÔÙ¹à×¢ºóÁ¢¼´½ÓÊÜ1×106EPCÒÆÖ²£¬È»ºó¼ì²âÄÔ¹£ÈûÌå»ý¡¢ÑªÄÔÆÁÕÏͨ͸ÐÔ¡¢½ôÃÜÁ¬½Óµ°°×±í´ïºÍȱÑõÓÕµ¼Òò×Ó-1ᣨhypoxia-inducible factor-1ᣬHIF-1ᣩmRNAˮƽ¡£½á¹ûÏÔʾ£¬Óë¶ÔÕÕ×éÏà±È£¬¶ÌÔÝÐÔÄÔȱѪºóEPCÒÆÖ²µÄÌÇÄò²¡Ð¡ÊóµÄÉñ¾­¹¦ÄÜȱËð¼õÈõ£¬ÄÔ¹£ÈûÌå»ý¼õÉÙ£¬ÑªÄÔÆÁÕÏÉø©ºÍ½ôÃÜÁ¬½Óµ°°×½µ½â¼õÉÙ£¬Í¬Ê±£¬EPCÒ²Éϵ÷ÁËHIF-1α±í´ï¡£±íÃ÷EPC¿Éͨ¹ýÉϵ÷HIF-1αÐźŴ«µ¼À´±£»¤ÌÇÄò²¡Ð¡Êó¾ÖÔîÐÔȱѪºóµÄѪÄÔÆÁÕÏÍêÕûÐÔ¡£PENAµÈ[22]¼ì²âÁËÁ£Ï¸°û¼¯Âä´Ì¼¤Òò×Ó£¨granulocyte colony stimulating factor,G-CSF£©ÔÚ¼õÉÙÑÓ³Ù×éÖ¯ÏËÈÜøԭ¼¤»îÎtissue plasminogen activator,tPA£©ÓÕµ¼µÄ³öѪÐÔת»¯£¨hemorrhagic transformation,HT£©£¬ÄÔ¹£ÈûºÍѪ˨˨Èû£¨thromboembolism,TE£©ÖзçÄ£ÐÍÖеÄÉñ¾­¹¦ÄÜȱËð·½ÃæµÄ¹¦Ð§£¬ÒÔ¼°G-CSFµÄ×÷ÓÃÊÇ·ñ³ÖÐø¸ü³¤Ê±¼ä»Ö¸´ÆÚ¡£ÔÚÖзçÓÕµ¼ºó6 h£¬·Ö±ð¸ø´óÊó¾²Âö×¢tPA(10 mg/kg£©»òG-CSF(300μg/kg)+t PA£¬²¢ÒÔÉúÀíÑÎË®×÷Ϊ¶ÔÕÕ£¬½á¹û·¢ÏÖ£¬G-CSFʹÑÓ³ÙµÄtPAÏà¹ØHT¼õÉÙÁË47%£¬¹£ÈûÌå»ý¼õÉÙÁË33%£¬Ô˶¯ºÍÉñ¾­¹¦ÄÜȱËð·Ö±ð¼õÉÙÁË15%ºÍ25%£»Í¬Ê±£¬ÃâÒß×黯½á¹ûÏÔʾ£¬È±ÑªÆ¤ÖʺÍÎÆ×´ÌåÖÐEPC±ê¼ÇÎïCD34+ºÍVEGFR2·Ö±ð¸»¼¯1.5ºÍ1.8±¶£»ÁíÍ⣬Á÷ʽϸ°ûÊõ½á¹ûÏÔʾ£¬¸øÓèG-CSFµÄ´óÊóÍâÖÜѪÖÐCD34+ϸ°ûµÄ¶¯Ô±Ôö¼Ó¡£ÕâЩ½á¹û֤ʵ£¬G-CSFÄܹ»Í¨¹ýÔöÇ¿EPC¶¯Ô±À´Ìá¸ßtPAÖÎÁÆʱ¼ä´°¿ÚµÄÓÐЧÐÔ¡£CHENµÈ[23]Ñо¿Ö¤Êµ£¬Í¨¹ý¾±ÄÚ¶¯ÂöÊä×¢À´×Ô×ÔÌåÍâÖÜѪµÄEPC£¬¿É¼õÉÙ´óÊóµÄ´óÄÔ¹£ÈûÇøºÍ¼±ÐÔȱѪÐÔ×äÖкóÉñ¾­¹¦ÄÜȱËð´óÄÔÖж¯Âö±ÕÈû¡£

¡¡¡¡×î½ü£¬PENGµÈ[24]¶Ô¾­¹ý14 dÀäѱ»¯ÆÚºóÓ×ÄêºÍÀÏÄêСÊó½øÐÐÓÀ¾ÃÐÔÄÔȱѪ£¬²¢½øÐÐ×é֯ѧ·ÖÎöºÍÐÐΪ²âÊÔ£¬·ÖÀëСÊóEPC£¬²â¶¨Æ书ÄܺÍÊýÁ¿£¬À´Ñо¿EPCÒÆÖ²¶ÔÄÔȱѪËðÉ˵ÄÓ°Ïì¡£½á¹ûÏÔʾ£¬ÄÔȱѪ·¢×÷Ç°µÄÔ¤·ÀÐÔÀäѱ»¯ÄÜÔö¼ÓEPC¹¦ÄÜ£¬´Ù½øȱѪÐÔÄÔѪ¹ÜÉú³É£¬±£»¤ÃâÊÜÄÔȱѪÐÔËðÉË£¬²¢¸ÄÉÆÓ×ÊóµÄ³¤ÆÚÖзç½á¹û£»´ËÍ⣬ÓëÀ´×Ô¶ÔÕÕСÊóµÄEPCÏà±È£¬À´×ÔÀ䱩¶СÊóµÄÒÆÖ²EPC¾ßÓиüÇ¿µÄ¼õÉÙÄÔȱѪËðÉ˺ʹٽø¾Ö²¿Ñª¹Ü·¢ÉúµÄÄÜÁ¦£¬Í¬Ê±£¬Ô¤·ÀÐÔÀäѱ»¯»¹¿ÉÔöÇ¿EPC¹¦ÄÜ£¬´Ù½ø¾Ö²¿Ñª¹ÜÉú³É£¬²¢Ô¤·ÀÀÏÄêСÊóµÄÄÔȱѪÐÔËðÉË¡£Òò´Ë£¬È±Ñª·¢×÷Ç°µÄÔ¤·ÀÐÔÀäѱ»¯Äܹ»²¿·ÖµØͨ¹ý´Ù½øEPCµÄÐÞ¸´¹¦ÄܸÄÉÆСÊóµÄ³¤ÆÚÖзç½á¹û£¬ÇÒƵ·±À䱩¶µÄÊÒÄÚ»·¾³±ä»¯¿ÉÄÜÓÐÀûÓÚÖзçµÄ¸ß·çÏÕÈËȺ¡£

¡¡¡¡2¡¢ EPCÓë»ùÒòÖÎÁÆ

¡¡¡¡2.1¡¢ EPCתȾVEGF

¡¡¡¡MENGµÈ[25]ÓÃÖØ×éµÄÏÙ²¡¶¾-VEGF-165(Ad-VEGF-165£©×ªÈ¾EPCºó½«ÆäÒÆÖ²ÖÁͨ¹ý²¿·Ö½áÔúÏÂÇ»¾²Âöµ¼ÖÂÂýÐÔ¾²ÂöѪ˨ÐγɵĴóÊóÄ£ÐÍÖУ¬À´Ì½ÌÖ¸Éϸ°ûÒÆÖ²Óë»ùÒòתȾ¶ÔÂýÐÔ¾²ÂöѪ˨ÐγɵÄЭͬÖÎÁÆ×÷Ó㬽á¹ûÏÔʾ£¬ÒÆֲתȾºóµÄEPC×é±í´ïµÄVEGF mRNAˮƽ×î¸ß£¬ÔÙͨëϸѪ¹ÜÃܶÈÃ÷ÏÔÉý¸ß£¬¶ÔÂýÐÔ¾²ÂöѪ˨µÄÔÙͨÓмÓËÙ×÷Óá£WANGµÈ[26]ÀûÓÃVEGF-165תȾEPC¹Û²ìÆä¶ÔÖ«ÌåȱѪ¼ÒÍÃÐÂÉúѪ¹ÜÐγɵÄÓ°Ï죬½á¹ûÏÔʾ£¬³É¹¦×ªÈ¾VEGF-165µÄEPC£¬ÆäÔöÖ³²»ÊÜתȾӰÏ죬ÓëEPCδתȾVEGH-165×éÏà±È£¬×ªÈ¾×éVEGFÉÏÇåµ°°×Ũ¶Èˮƽ¼°Ã«Ï¸Ñª¹ÜÃܶÈÃ÷ÏÔÉý¸ß£¬¶ÔÍÃÖ«ÌåȱѪµÄ±»VEGH-165תȾµÄEPCÒÆÖ²·´Ó¦Ã÷ÏÔºÃÓÚµ¥¶ÀEPCÒÆÖ²¡£

¡¡¡¡2.2¡¢ EPCתȾe NOS

¡¡¡¡CUIµÈ[27]ͨ¹ýʵÑé֤ʵÁËEPCÖÐeNOSµÄ¹ý±í´ïÔöÇ¿Á˶ÔÐÂÄÚĤÔöÉúµÄÒÖÖÆ£¬²¢»Ö¸´ÁËÊÜËðѪ¹ÜÖÐÄÚƤÒÀÀµÐÔѪ¹ÜÊæÕÅ£¬ÒÆÖ²¹ý±í´ïeNOSµÄEPC¿Éͨ¹ýÒÖÖÆÐÂÄÚĤÔöÉúºÍ»Ö¸´Ñª¹Ü¹¦ÄÜÀ´ÐÞ¸´ÊÜËðѪ¹Ü¡£DANGµÈ[28]ÀûÓÃÖ¬ÖÊÌå½éµ¼eNOSÌåÍâתȾСÊó¹ÇËèÀ´Ô´µÄEPC£¬½á¹û±íÃ÷£¬×ªÈ¾48 hºó£¬EPCÖÐe NOS±í´ïÁ¿Ã÷Ôö¼Ó£¬NOº¬Á¿Ã÷ÏÔÉý¸ß£¬ROSº¬Á¿Ã÷ÏÔ½µµÍ£¬Ö¬ÖÊÌå½éµ¼eNOS»ùÒòÄܹ»ÓÐЧתȾСÊóEPC£¬²¢ÄÜÔÚEPCÖÐÓÐЧ±í´ï¡£

¡¡¡¡2.3¡¢ EPCתȾ¶ËÁ£Ã¸Äæת¼ø

¡¡¡¡ZHANGµÈ[29]½«¶ËÁ£Ã¸Äæת¼øתȾµÄEPCÒÆÖ²ÖÁ¾­Àú¹ý6´ÎÈ«ÉöÇгýÊõµÄ´óÊóÄ£ÐÍÖУ¬Ö¤ÊµÁËתȾºóµÄEPCÄܹ»¸ÄÉÆÉö¹¦ÄÜ£¬¼õÉÙ¹ÜÖÜ΢Ѫ¹ÜµÄËðʧ£¬²¢ÒÖÖÆÉö¼äÖÊÏËά»¯µÄ½øÕ¹¡£

¡¡¡¡2.4¡¢ EPCתȾÆäËû»ùÒò

¡¡¡¡SONGµÈ[30]ÓøÎϸ°ûÉú³¤Òò×Ó£¨hepatocyte growth factor,HGF£©×ªÈ¾EPC¹Û²ìHGFתȾ¶ÔEPCÔöÖ³¡¢Ç¨ÒƺÍѪ¹ÜÉú³ÉµÄÓ°Ï죬ÒÔ¼°×ªÈ¾µÄEPC¶Ô¸ßµ¨¹Ì´¼ÑªÖ¢´óÊóÇòÄÒÓÕµ¼µÄ¶¯ÂöËðÉ˺óÐÂÄÚĤÐγɵÄÓ°Ïì¡£Ñо¿½á¹ûÏÔʾ£¬ÓÃHGFתȾµÄEPC¿ÉÊͷųö¸ßˮƽµÄ¿ÉÈÜÐÔHGFµ°°×£¬Í¬Ê±Ò²ÔöÇ¿ÁËEPCµÄÔöÖ³¡¢Ç¨ÒƺÍѪ¹ÜÉú³ÉÄÜÁ¦£¬×ªÈ¾ºóµÄEPCÔÚ´óÊóÄ£ÐÍÖÐÄܹ»¸üÓÐЧµØ¼õÉÙÐÂÄÚĤÐγɺÍÔö¼ÓÔÙÄÚƤ»¯¡£Òò´Ë£¬HGFתȾEPC¿ÉÄÜÊÇÔ¤·ÀѪ¹ÜËðÉ˺óÐÂÄÚĤÐγɵÄʵÓÃÇÒÓÐÏ£ÍûµÄÁÆ·¨¡£CAOµÈ[31]ÓÃÈËȱÑõÓÕµ¼Òò×Ó-1ᣨhuman hypoxia-inducible factor-1ᣬhHIF-1α£©×ªÈ¾EPC£¬²¢½«×ªÈ¾ºóµÄEPCÒÆÖ²ÖÁ³É¹¦¹¹½¨µÄ»¼Óзζ¯Âö¸ßѹ£¨pulmonary hypertension,PAH£©µÄÍÃÄ£ÐÍÖУ¬ÔÚÆäÒÆÖ²ÖÁÍÃ2Öܺó£¬Ó¦Óõ¼¹Ü²åÈëÊõÀ´ÊÕ¼¯ÑªÒº¶¯Á¦Ñ§Êý¾Ý£¬Í¬Ê±Í¨¹ý²âÁ¿ÓÒÐÄÊÒ·Ê´óÖ¸Êý¡¢ÄÚ²à±Úºñ¶ÈºÍÄÚ²à±ÚÇøÓòÀ´ÆÀ¹ÀÓÒÐÄÊÒ·Ê´óºÍ·ÎѪ¹ÜÖØËÜ¡£µ°°×Ó¡¼Ç·¨ºÍÃâÒß×黯·ÖÎöÓÃÓÚ¼ì²â·ÎС¶¯ÂöÖÐhHIF-1αµÄ±í´ï¡£½á¹ûÏÔʾ£¬ÔÚתȾEPCÒÆÖ²2Öܺó£¬ÊÕËõÆڷζ¯ÂöѹºÍƽ¾ù·Î¶¯Âöѹ¾ù¼õÈõ£»ÓÒÐÄÊÒ·Ê´óºÍ·ÎѪ¹ÜÖØËܱ»Äæת£»´ËÍ⣬hHIF-1αÔÚÒÆÖ²µÄתȾEPCÖбí´ïÔö¸ß£¬·ÎС¶¯ÂöµÄÊýÁ¿Ôö¼Ó¡£±íÃ÷ÓÃHIF-1αתȾµÄEPCÖÎÁÆPAH¿ÉÄÜÊÇÒ»ÖÖ°²È«ÓÐЧµÄ·½·¨¡£HUµÈ[32]½«»ùÖÊϸ°ûÑÜÉúÒò×Ó-1(stromal cell derived factor-1,SDF-1£©ºÍѪ¹ÜÄÚƤÉú³¤Òò×Ó£¨vascular endothelial growth factor,VEGF£©×ªÈ¾ÖÁEPCÖУ¬²¢½«×ªÈ¾ºóµÄEPCÒÆÖ²ÖÁÄÔ¹£ËÀ´óÊóÄ£ÐÍÖУ¬½á¹ûÏÔʾ£¬VEGF165ºÍSDF-1µÄ¹²±í´ï¸ÄÉÆÁËÄÔ¹£ËÀ´óÊóµÄÉñ¾­¹¦ÄÜ£¬¼õÉÙÁËÄÔ¹£ÈûÌå»ý£¬Ôö¼ÓÁË΢Ѫ¹ÜÃܶȣ¬´Ù½øÁËȱѪ°ëÓ°ÖеÄѪ¹ÜÉú³É£¬¸ÄÉÆÁËÄÔѪÁ÷Á¿ºÍ¹à×¢£¬Òò´Ë£¬VEGF165ºÍSDF-1»ùÒòÁªºÏÖÎÁÆ¿ÉÄÜÊǸÄÉÆÄÔ¹£ËÀºóѪ¹ÜÖØËܺͻָ´Éñ¾­¹¦ÄܵÄDZÔÚ²ßÂÔ¡£LIµÈ[33]Ñо¿ÁËÇ÷»¯Òò×ÓCXCL12תȾºóµÄEPCÔÚȱѪÐÔÖзçСÊóÄ£ÐÍÖеÄ×÷Ó㬽á¹ûÏÔʾ£¬CXCL12-EPCÖÎÁÆÔÚÄÔȱѪºó5ÖÜÏÔ׿õÉÙÁËСÊóÄÔήËõ²¢¸ÄÉÆÆäÉñ¾­ÐÐΪ¹¦ÄÜ£¬Ñª¹ÜÃܶȺÍËèÇÊÍêÕûÐÔÔö¼Ó£¬´Ù½øÉñ¾­Ðγɣ¬Ñª¹ÜÉú³É£¬CXCL12תȾµÄEPCÔÚÖÎÁÆȱѪÐÔÖз緽Ãæ¾ßÓо޴óDZÁ¦¡£KEµÈ[34]Óñí´ïβ2ARµÄÏÙ²¡¶¾ÑªÇåתȾÈËEPC£¬½á¹û±íÃ÷£¬×ªÈ¾ºóµÄEPC¹ý±í´ïβ2AR¿ÉÔöÇ¿ÌåÍâEPC¹¦ÄÜ£¬²¢Í¨¹ýβ2AR/Akt/eNOS;¾¶ÔöÇ¿ÌåÄÚEPCµÄѪ¹ÜÐÞ¸´ÄÜÁ¦¡£

¡¡¡¡3¡¢ Õ¹Íû

¡¡¡¡×ÛÉÏËùÊö£¬Ä¿Ç°¹ØÓÚEPCÔÚÖÎÁÆȱѪÐÔÐÄÔಡ¡¢Ô¤·ÀÖ§¼ÜÊõºóÔÙÏÁÕ­¡¢ÖÎÁÆȱѪÐÔÄÔѪ¹Ü²¡¼°Ö«ÌåȱѪÐÔ¼²²¡µÈ·½ÃæµÄÑо¿¾ùÈ¡µÃÁËÒ»¶¨µÄ½øÕ¹£¬¸øȱѪÐÔ¼²²¡»¼ÕßµÄÖÎÁÆ´øÀ´ÁËÏ£Íû¡£ÏàÐÅËæ×ÅEPCÔÚÔÙÉúҽѧÑо¿ÖеIJ»¶ÏÉîÈ룬ÔÚ²»¾ÃµÄ½«À´£¬EPCÓÐÏ£Íû³ÉΪÖÎÁÆȱѪÐÔ¼²²¡µÄÓÖÒ»ÀûÆ÷¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1] SEN S,MERCHAN J,DEAN J,et al. Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction[J]. Hum Gene Ther,2010,21(10):1327-1334.
¡¡¡¡[2] LEE F Y,CHEN Y L,SUNG P H,et al. Intracoronary transfusion of circulation-derived CD34+cells improves left ventricular function in patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention[J]. Crit Care Med,2015,43(10):2117-2132.
¡¡¡¡[3] KAMATA S,MIYAGAVA S,FUKUSHIMA S,et al. Improvement of cardiac stem cell sheet therapy for chronic ischemic injury by adding endothelial progenitor cell transplantation:analysis of layer-specific regional cardiac function[J]. Cell Transplant,2014,23(10):1305-1319.
¡¡¡¡[4] QUAN Z,WANG Q L,ZHOU P,et al. Thymosinβ4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium[J]. Int J Mol Med,2017,39(6):1347-1356.
¡¡¡¡[5] PREMER C,BLUM A,BELLIO M A,et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells[J]. Ebiomedicine,2015,2(5):467-475.
¡¡¡¡[6] FU W L,XIANG Z,HUANG F G,et al. Combination of granulocyte colony-stimulating factor and CXCR4 antagonist AMD-3100 for effective harvest of endothelial progenitor cells from peripheral blood and in vitro formation of primitive endothelial networks[J]. Cell and Tissue Banking,2016,17(1):161-169.
¡¡¡¡[7] GUERRA G,PERROTTA F,TESTA G. Circulating endothelial progenitor cells biology and regenerative medicine in pulmonary vascular diseases[J]. Curr Pharm Biotechnol,2018,19(9):700-707.
¡¡¡¡[8] MONIKA G J,EDYTA P,MACHALINSKI BOGUSLAW M,et al. Effects of angiotensin-converting enzyme inhibition on circulating endothelial progenitor cells in patients with acute ischemic stroke[J]. Stem Cells Int,2018,2018(4):1-10.
¡¡¡¡[9] GREENWALD A C,LICHT T,KUMAR S,et al. VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells[J]. J Exp Med,2019,216(1):215-230.
¡¡¡¡[10] SANDHU K,MAMAS M,BUTLER R. Endothelial progenitor cells:Exploring the pleiotropic effects of statins[J]. World J Cardiol,2017,9(1):1-13.
¡¡¡¡[11] CHEN J Z,WANG X X,ZHU J H,et al. Effects of Ginkgo Biloba extract on number and activity of endothelial progenitor cells from peripheral blood[J]. J Cardiovascular Pharmacol,2004,43(3):347-352.
¡¡¡¡[12] HONOLD J,LEHMANN R,HEESCHEN C,et al. Effects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease[J]. Arterioscler Thromb Vasc Biol,2006,26(10):2238-2243.
¡¡¡¡[13] DENG J,YUAN S,LI X,et al. Heparin/DNA aptamer coassembled multifunctional catecholamine coating for EPC capture and improved hemocompatibility of vascular devices[J].Mater Sci Eng C Mater Biol Appl,2017,79(5):305-314.
¡¡¡¡[14] MIGLIONIC M,PATTI G,D'AMBROSIO A,DI SCIASCIO G.Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent:a prospective single-center registry in highrisk patients[J]. Catheter Cardiovasc Interv,2008,71(5):600-604.
¡¡¡¡[15] BARSOTTI M,DI STEFANO R,SPONTONI P,et al. Role of endothelial progenitor cell mobilization after percutaneous angioplasty procedure[J]. Curr Pharm Design,2009,15(10):1107-1122.
¡¡¡¡[16] CHEN W,ZENG W,SUN J,et al. Construction of an aptamer-SiRNA chimera-modified tissue-engineered blood vessel for cell-type-specific capture and delivery[J]. Acs Nano,2015,9(6):6069-6076.
¡¡¡¡[17] WOUDSTRA P,KALKMAN D N,DEN H P,et al. 1-Year Results of the REMEDEE registry:clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered(Combo)stent in a multicenter,prospective all-comers registry[J].JACC Cardiovasc Interv,2016,9(11):1127-1134.
¡¡¡¡[18] MEAMAR R,NIKYAR H,DEHGHANI L,et al. The role of endothelial progenitor cells in transient ischemic attack patients for future cerebrovascular events[J]. J Res Med Sci,2016,21(1):47.
¡¡¡¡[19] LI Y,FENG H,YU Q,et al. Constitutive expression of adiponectin in endothelial progenitor cells protects a rat model of cerebral ischemia[J]. Neural Plasticity,2017,2017(10):1-8.
¡¡¡¡[20] MORANCHO A,MA F,BARCELO V,et al. Impaired vascular remodeling after endothelial progenitor cell transplantation in MMP9-deficient mice suffering cortical cerebral ischemia[J]. J Cerebral Blood Flow&Metab,2015,35(10):1547-1551.
¡¡¡¡[21] GENG J,WANG L,QU M,et al. Endothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1α[J]. Stem Cell Res&Ther,2017,8(1):163.
¡¡¡¡[22] PENA I D,YANG S,SHEN G,et al. Extension of tissue plasminogen activator treatment window by granulocyte-colony stimulating factor in a thromboembolic rat model of stroke[J].Int J Mol Sci,2018,19(6):1-12.
¡¡¡¡[23] CHEN Y L,TSAI T H,WALLACE C G,et al. Intra-carotid arterial administration of autologous peripheral blood-derived endothelial progenitor cells improves acute ischemic stroke neurological outcomes in rats[J]. Int J Cardiol,2015,201(12):668-683.
¡¡¡¡[24] PENG C,WANG L P,TAO X,et al. Preventive cold acclimation augments the reparative function of endothelial progenitor cells in mice[J]. Cell Physiol Biochem,2018,45(1):175-191.
¡¡¡¡[25] MENG Q Y,LI X Q,YU X B,et al. Transplantation of VEGF-165-gene-transfected endothelial progenitor cells in the treatment of chronic venous thrombosis in rats[J]. Chin Med J(Engl),2010,123(4):471-477.
¡¡¡¡[26] WANG S,CHEN Z,TANG X,et al. Transplantation of vascular endothelial growth factor165-transfected endothelial progenitor cells for the treatment of limb ischemia[J]. Mol Med Rep,2015,12(4):4967-4974.
¡¡¡¡[27] CUI B,HUANG L,FANG Y,et al. Transplantation of endothelial progenitor cells overexpressing endothelial nitric oxide synthase enhances inhibition of neointimal hyperplasia and restores endothelium-dependent vasodilatation[J]. Microvascular Res,2011,81(1):143-150.
¡¡¡¡[28] DANG S C,CHEN R F,WANG P J,et al. Experimental study on endothelial nitric oxide synthase gene transfecting in murine endothelial progenitor cells[J]. Guangdong Med J,2014,35(22):3464-3467.(in Chinese)µ³Ê¤´º£¬³ÂÈÙ·¼£¬Íõƽ½­£¬µÈ.Ò»Ñõ»¯µªºÏø»ùÒòתȾСÊóÄÚƤ×æϸ°ûµÄʵÑéÑо¿[J].¹ã¶«Ò½Ñ§£¬2014,35(22):3464-3467.
¡¡¡¡[29] ZHANG Y,WANG T,YANG J,et al. Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase[J]. Oncotarget,2016,7(26):39302-39315.
¡¡¡¡[30] SONG M B,YU X J,ZHU G X,et al. Transfection of HGF gene enhances endothelial progenitor cell(EPC)function and improves EPC transplant efficiency for balloon-induced arterial injury in hypercholesterolemic rats[J]. Vascular Pharmacol,2009,51(2):205-213.
¡¡¡¡[31] CAO G,LIU C,WAN Z,et al. Combined hypoxia inducible factor-1αand homogeneous endothelial progenitor cell therapy attenuates shunt flow-induced pulmonary arterial hypertension in rabbits[J]. J Thoracic Cardiovascular Surg,2015,150(3):621-632.
¡¡¡¡[32] HU G J,FENG Y G,LU W P,et al. Effect of combined VEGF-165/SDF-1 gene therapy on vascular remodeling and blood perfusion in cerebral ischemia[J]. J Neurosurg,2017,127(3):1-9.
¡¡¡¡[33] LI Y,CHANG S,LI W,et al. cxcl12-engineered endothelial progenitor cells enhance neurogenesis and angiogenesis after ischemic brain injury in mice[J]. Stem Cell Res&Ther,2018,9(1):139-154.
¡¡¡¡[34] KE X,SHU X R,WU F,et al. Overexpression of theβ2AR gene improves function and re-endothelialization capacity of EPCs after arterial injury in nude mice[J]. Stem Cell Res&Ther,2016,7(1):73-86.

×÷Õßµ¥Î»£º¸ÊËàÖÐÒ½Ò©´óѧÁÙ´²Ò½Ñ§Ôº ½â·Å¾üÁªÇÚ±£Õϲ¿¶ÓµÚ¾ÅËÄ©–Ò½Ôº¼ìÑé¿Æ ¸ÊËàÊ¡¸Éϸ°ûÓë»ùÒòÒ©ÎïÖصãʵÑéÊÒ
Ô­Îijö´¦£ºÀîÐÀ,½¯ÈçÈç,¹þСÇÙ.ÄÚƤ×æϸ°ûÔÚÔÙÉúҽѧÖеÄÓ¦ÓÃ[J].ÖйúÉúÎïÖÆƷѧÔÓÖ¾,2020,33(04):449-454.
Ïà¹ØÄÚÈÝÍƼö
Ïà¹Ø±êÇ©£º
·µ»Ø£ºÏ¸°ûÉúÎïѧÂÛÎÄ